Zoetis Inc.

ZTS

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep.

About the company

Country: United StatesPrice: $83.82Market Cap: $34.1B

Investment snapshot

35%positive consensus

Scored 1d ago

Positive

BUY / PASS

Neutral / negative

5 / 6

NEUTRAL / FAIL

Median fair value

$73.26

-12.6% vs price

Models with upside

3 / 17

Positive margin of safety

Strongest signal

8 of 10 pass — Dreman and Oshaughnessy object

Key risk

11 of 12 flag ZTS's debt & leverage — Graham, Buffett, Lynch +8 more

Framework analysis

Verdict	Meaning
BUY	Positive purchase signal: the framework's buy requirements are met.
PASS	The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRAL	Neither a positive nor negative conclusion. It does not mean to hold an existing position.
FAIL	The company does not clear the framework's requirements.
Ranked	Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

Metric	Graham Defensive Value	Buffett Quality Compounder	Lynch GARP	Greenblatt Magic Formula	Piotroski F-Score	Dreman Contrarian Value	Munger Quality Focus	Pabrai Dhandho Framework	Akre Three-Legged Stool	Marks Risk-Aware Value	Ackman Activist Value	Templeton Global Bargain Hunter	Sleep Scale Economies Shared	Asness Systematic Factors	Neff Low-P/E Total Return	Schloss Asset-Value Discipline	O'Shaughnessy Systematic Factor Composite
Verdict	PASS	FAIL	FAIL	BUY · Rank #329 (Top 10.6%)	NEUTRAL	PASS	PASS	NEUTRAL	FAIL	NEUTRAL	NEUTRAL	PASS	NEUTRAL	FAIL	PASS	FAIL	FAIL
Score
Analysis	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…
Intrinsic Value (annual)					N/A								N/A	N/A	N/A	N/A	N/A
Margin of Safety	-157.2%	+45.0%	-16.3%	-33.7%	N/A	-1.2%	-14.4%	-20.4%	+0.7%	-46.4%	+13.4%	-10.3%	N/A	N/A	N/A	N/A	N/A
Financial Basis	TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025 Latest source filing: 2026-11-05 Score computed: 2026-11-14	Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14	Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14	TTM ended 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2026-02-12 Score computed: 2026-11-14	Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-05 Score computed: 2026-11-14	Qualitative assessment · Annual history · FY 2025 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14	Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-02-12 Score computed: 2026-11-14	Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14	Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment Latest source filing: 2026-11-05 Score computed: 2026-11-14	Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-05 Score computed: 2026-11-14	Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14	Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-02-12 Score computed: 2026-11-14	TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-11-05 Score computed: 2026-11-14	Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14	Annual history · FY 2025 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14	TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-11-05 Score computed: 2026-11-14

Where It Passes

Cash Flow80% pass✓ 10✗ 2▾
8 of 10 pass — Dreman and Oshaughnessy object
Free Cash Flow Proxy$2.6B
✓BuffettPositive and growing
FCF Positive and Growing$2.3B
✓LynchPositive and growing
Operating Cash Flow$2.9B
✓PiotroskiCFO > 0
(CFO / Total Assets) vs ROACFO/Assets=18.78%, ROA=17.28%
✓PiotroskiCFO/Assets > ROA
Price / (CFO / Shares)12.3x
✗Dreman< 8x
P/E or FCF YieldP/E=13.9x, FCF Yield=6.7%
✓PabraiP/E < 15 or FCF Yield > 10%
FCF Positive15/15 years FCF positive
✓MarksPositive FCF in majority of recent years
(OCF - CapEx) / Market Cap6.4%
✓Ackman>= 4%
Price / FCF per Share15.6x
✓Ackman<= 25
Positive Operating Cash Flow frequency15/15 years positive
✓SleepPositive OCF in >= 70% of available years
Operating Cash Flow - Capital Expenditures$2.3B
✓Neff> $0 (app proxy for a strong fundamental case)
(Operating cash flow - capex) / market capitalization+6.69%; #1228/4519 (top 27.2%)
✗OshaughnessyTop 10% of eligible cross-section
Growth75% pass✓ 10✗ 3▾
6 of 8 pass — Lynch and Sleep object
EPS Growth (3-yr avg, 10-yr window)711.8%
✓Graham>= 33% growth
Basic earnings-growth PEG (dividends excluded)1.16
✗Lynch< 1.0 (ideally < 0.5)
3-5 Year EPS CAGR12.0%
✓Lynch15-30% (Fast Grower); > 0% to pass
Inventory Growth vs Revenue GrowthInv: 2.9% vs Rev: 1.2%
✗LynchInventory growth < Revenue growth
EPS Growth Direction$0.49 (2011) -> $6.02 (2025)
✓DremanPositive over recent years
EPS CAGR19.6% CAGR over 14 years
✓Dreman> 5% annualized
Positive Net Income Frequency15/15 years positive
✓MarksPositive net income in >= 7 of last 10 years
3yr Median Revenue Growth5.7%
✓Ackman>= 5%
Positive EPS Growth Frequency5/5 years with positive EPS growth
✓AckmanPositive EPS growth in >= 3 of last 5 years
5-Year EPS CAGR12.0% CAGR over 5 years
✓Templeton> 0% (5-year EPS CAGR)
Revenue growth vs. gross and operating margin trend
✗SleepRevenue rising; gross margin flat or falling; operating margin holding
5-year Revenue CAGR7.2%
✓SleepCAGR > 7%
3-5 Year Diluted EPS CAGR12.0% over 5 years
✓Neff7%-20% annualized

Where It Falls Short

Debt & Leverage8% pass✓ 3✗ 12▾
11 of 12 flag ZTS's debt & leverage — Graham, Buffett, Lynch +8 more
LT Debt vs Net Current AssetsLT Debt $8.3B vs NCA $3.6B
✗GrahamLT Debt <= Net Current Assets
Debt/Equity & Interest CoverageD/E: 2.74, IC: 13.9x
✗BuffettD/E < 0.5 AND Interest Coverage > 5x
Total Debt / Equity2.74
✗Lynch< 0.33
Cash - Long-term Debt$-7.0B
✗LynchPositive preferred
LT Debt / Total Assets Change36.67% -> 58.46%
✗PiotroskiDecreased YoY
Current Assets / Current Liabilities2.35
✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
Total Debt / Shareholders' Equity2.74
✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
Debt Levels2.74
✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
Interest Coverage & Debt/EBITDAIC=13.9x, D/EBITDA=2.4x
✓MarksInterest Coverage > 3x; Debt/EBITDA < 4x
Total Debt / Shareholders Equity2.74
✗Ackman<= 1.0
Negative debt-to-equity (higher means less debt)-2.7396; #3897/4210 (top 92.6%)
✗AsnessTop 30% of eligible cross-section
Valuation models27% pass✓ 3✗ 8▾
Models split on ZTS at $83.82 — fair values range $32.59–$152.44
Graham fair value$32.59
✗Graham-157.2% margin vs $83.82
Buffett fair value$152.44
✓Buffett+45.0% margin vs $83.82
Lynch fair value$72.08
✗Lynch-16.3% margin vs $83.82
Greenblatt fair value$62.68
✗Greenblatt-33.7% margin vs $83.82
Dreman fair value$82.80
✗Dreman-1.2% margin vs $83.82
Munger fair value$73.26
✗Munger-14.4% margin vs $83.82
Pabrai fair value$69.59
✗Pabrai-20.4% margin vs $83.82
Akre fair value$84.44
✓Akre+0.7% margin vs $83.82
Marks fair value$57.27
✗Marks-46.4% margin vs $83.82
Ackman fair value$96.79
✓Ackman+13.4% margin vs $83.82
Templeton fair value$75.96
✗Templeton-10.3% margin vs $83.82
Valuation31% pass✓ 8✗ 20▾
9 of 13 flag ZTS's valuation — Graham, Lynch, Greenblatt +6 more
Net income / market capitalization+7.30%; #1125/6340 (top 17.7%)
✓AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
Price / 3-yr avg EPS15.2x
✗Graham<= 15x
Price-to-Book Ratio10.7x
✗Graham<= 1.5x
P/E x P/B162.40
✗Graham<= 22.5
Basic earnings-growth PEG (dividends excluded)1.16
✗Lynch< 1.0 (ideally < 0.5)
EBIT / Enterprise Value8.0%
✗Greenblatt> 10%
Earnings Yield + ROC AssessmentEY=8.0%, ROC=49.3%
✗GreenblattBoth EY > 10% and ROC > 25%
Price / EPS13.9x
✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
Price / (CFO / Shares)12.3x
✗Dreman< 8x
Price / Book Value per Share10.7x
✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
Valuation ReasonablenessP/E=13.9x, OE Yield=7.1%
✓MungerP/E < 25 or Owner Earnings Yield > 5%
P/E or FCF YieldP/E=13.9x, FCF Yield=6.7%
✓PabraiP/E < 15 or FCF Yield > 10%
P/B or P/E vs. Historical AverageP/E=13.9x, P/B=10.7x
✓MarksP/E < 15 or P/B < 2.0
Discount to Intrinsic Value-1.2% (IV=$82.80 vs Price=$83.82)
✗Marks>= 20% below intrinsic value
Price / FCF per Share15.6x
✓Ackman<= 25
Price vs. Trailing Low119% of trailing low ($70.30)
✓Templeton<= 120% of trailing low (certified split-adjusted live window)
Positive book equity / market capitalization+0.0970; #4764/6449 (top 73.9%)
✗AsnessTop 30% of eligible cross-section
Price / Diluted EPS13.9x
✓NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
(EPS CAGR % + Dividend Yield %) / P/E1.04
✓Neff> 0.7 (Neff's published traditional edge)
Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
✗SchlossP/TBV <= 1.00x (app cutoff)
Book Value per Share Change-1.1%
✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
Revenue / market capitalization+0.2792; #3419/5247 (top 65.2%)
✗OshaughnessyTop 10% of eligible cross-section
(Operating cash flow - capex) / market capitalization+6.69%; #1228/4519 (top 27.2%)
✗OshaughnessyTop 10% of eligible cross-section
Trailing six-month price return through the evaluation date-28.88%; #4370/6202 (top 70.5%)
✗OshaughnessyTop 10% of eligible cross-section
Profitability38% pass✓ 21✗ 14▾
10 of 16 flag ZTS's profitability — Graham, Buffett, Lynch +7 more
Net income / market capitalization+7.30%; #1125/6340 (top 17.7%)
✓AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
Positive EPS (10 years)15/16 years positive
✗GrahamPositive EPS every year for 10 years
EPS Growth (3-yr avg, 10-yr window)711.8%
✓Graham>= 33% growth
Net Income Positive (10+ years)15/16 years positive
✗BuffettPositive every year for 10+ years
ROE (up to 5-year arithmetic mean)54.4%
✓Buffett> 15% arithmetic mean (app rule)
Operating Margin (10-yr trend)
✗BuffettStable or rising over 10 years
Free Cash Flow Proxy$2.6B
✓BuffettPositive and growing
Earnings Variance (10-yr CoV)0.65
✗BuffettCoV < 0.3
Retained Earnings Effectiveness
✗Buffett$1 retained -> > $1 market value created
Basic earnings-growth PEG (dividends excluded)1.16
✗Lynch< 1.0 (ideally < 0.5)
3-5 Year EPS CAGR12.0%
✓Lynch15-30% (Fast Grower); > 0% to pass
ROE75.3%
✓Lynch> 15%
EBIT / Enterprise Value8.0%
✗Greenblatt> 10%
Earnings Yield + ROC AssessmentEY=8.0%, ROC=49.3%
✗GreenblattBoth EY > 10% and ROC > 25%
Net Income / Total Assets17.28%
✓PiotroskiROA > 0
ROA Change YoY17.46% -> 17.28% (delta: -0.18%)
✗PiotroskiCurrent ROA > Prior ROA
(CFO / Total Assets) vs ROACFO/Assets=18.78%, ROA=17.28%
✓PiotroskiCFO/Assets > ROA
Gross Margin Change YoY70.6% -> 71.8%
✓PiotroskiImproved YoY
Pre-Tax Income / Revenue32.8%
✓Dreman>= 8%
Net Income / Shareholders' Equity75.3%
✓Dreman> 12%
Margin of SafetyP/E=13.9x, P/B=10.7x
✓PabraiP/B < 1.5 or P/E < 15
Return on Equity59.8% (3-yr avg)
✓AkreROE > 20% (3-year avg)
Discount to Intrinsic Value-1.2% (IV=$82.80 vs Price=$83.82)
✗Marks>= 20% below intrinsic value
Positive Net Income Frequency15/15 years positive
✓MarksPositive net income in >= 7 of last 10 years
Operating Income / Revenue
✗Ackman>= 15%
Net Income / Shareholders Equity75.3%
✓Ackman>= 15%
5-Year EPS CAGR12.0% CAGR over 5 years
✓Templeton> 0% (5-year EPS CAGR)
Operating Margin Trend
✗TempletonNon-negative operating-margin trend over 3 years
Revenue growth vs. gross and operating margin trend
✗SleepRevenue rising; gross margin flat or falling; operating margin holding
Gross profit / total assets+43.97%; #829/3702 (top 22.4%)
✓AsnessTop 30% of eligible cross-section
Net income / positive book equity+75.26%; #125/5226 (top 2.4%)
✓AsnessTop 30% of eligible cross-section
Negative 5-year standard deviation of ROA-0.0135; #1048/5884 (top 17.8%)
✓AsnessTop 30% of eligible cross-section
3-5 Year Diluted EPS CAGR12.0% over 5 years
✓Neff7%-20% annualized
Positive Diluted-EPS Years10/10 years positive
✓Schloss>= 70% positive over 5-10 observed years (app rule)
Efficiency38% pass✓ 4✗ 7▾
5 of 8 flag ZTS's efficiency — Buffett, Piotroski, Munger +2 more
Current Ratio2.35
✓Graham>= 2.0
ROIC (3-5 yr avg)
✗Buffett> 10%
ROIC - WACC
✗BuffettPositive (WACC = 10%)
EBIT / (NWC + Net Fixed Assets)49.3%
✓Greenblatt> 25%
Current Ratio Change YoY1.75 -> 3.03
✓PiotroskiIncreased YoY
Revenue / Total Assets Change YoY0.65x -> 0.61x
✗PiotroskiImproved YoY
Current Assets / Current Liabilities2.35
✓Dreman> 1.5
Return on Invested Capital
✗Munger> 15%
ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
Reinvestment Rate x ROIC
✗AkreReinvestment Rate * ROIC > 10%
ROIC (5-year)
✗SleepROIC > 12% in a majority of years
Verdicts50% pass✓ 6✗ 6▾
Split decision: 6 FAIL · 5 PASS · 5 NEUTRAL
Overall verdict
✓GrahamPASS (4/9)✗BuffettFAIL (2/9)✗LynchFAIL (3/7)✓GreenblattRank #329•PiotroskiNEUTRAL (F-Score 6)✓DremanPASS (6/11)✓MungerPASS (2/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (2/6)•MarksNEUTRAL (4/5)•AckmanNEUTRAL (7/9)✓TempletonPASS (4/8)•SleepNEUTRAL (4/6)✗AsnessFAIL (Rank #1170/2370 (Top 49.4%))✓NeffPASS (6/6)✗SchlossFAIL (3/7)✗OshaughnessyFAIL (Rank #419/963 (Top 43.5%))

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products

SIC Sector: Chemicals & Pharmaceuticals

Size: Large Cap($34.1B)

Revenue: $9.5B+2.3% YoY

Net Income: $2.7B+7.5% YoY

Financial Snapshot

Operating Margin--

Return on Equity80.2%

Debt / Equity2.71

Current Ratio3.03

EPS (Diluted)$6.02+10.1% 1y

Buybacks (1y)$3.2B

Buybacks (2y)$5.1B

Shares Retired5.3% / 7.3% 2y

Similar Companies

MRKMerck & Co., Inc.

$364.3B

ABTABBOTT LABORATORIES

$188.0B

BMYBRISTOL MYERS SQUIBB CO

$129.7B

TECHBIO-TECHNE Corp

$11.4B

Shareholder Return

Fiscal 2025

Retired 5.3% of shares last year, 7.3% over two.

Buybacks: $3.2B
Dividends: $889.0M

What drove EPS

A buyback raises earnings per share without the company earning more. This splits each year's change into the two.

FY22

5.2% = 3.8% + 1.3%

FY23

12.9% = 10.9% + 1.8%

FY24

7.9% = 6.1% + 1.7%

FY25

10.1% = 7.5% + 2.4%

Earnings Fewer shares More shares

Share count is the denominator the filer used for diluted EPS, recovered as net income ÷ EPS — not the balance-sheet count, which is a point-in-time figure and would put the timing difference into this split. Years with a loss are omitted: a smaller share count makes a loss per share larger, so the decomposition inverts.

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

Metric	TTM · 2026-09-30 2025-10-01 – 2026-09-30 Sources · derived quarter values 10-K · 2026-02-12 10-Q · 2026-05-07 10-Q · 2026-08-06 10-Q · 2026-11-05 Derived from cumulative filings: revenue, net income, pre tax income, interest expense, operating cash flow, depreciation amortization, capex, dividends paid, buybacks.	Q3 FY 2026 2026-07-01 – 2026-09-30 Sources · derived quarter values 10-Q · 2026-11-05 Derived from cumulative filings: operating cash flow, capex, dividends paid, buybacks.	Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter values 10-Q · 2026-08-06 Derived from cumulative filings: operating cash flow, capex, dividends paid, buybacks.	Q1 FY 2026 2026-01-01 – 2026-03-31 Sources 10-Q · 2026-05-07	FY 2025 Sources 10-K · 2026-02-12	FY 2024 Sources 10-K · 2025-02-13	FY 2023 Sources 10-K · 2024-02-13	FY 2022 Sources 10-K · 2023-02-14	FY 2021 Sources 10-K · 2022-02-15
Market Cap	$34.1Bcurrent	--	--	--	$52.8Best.	$75.3Best.	$83.8Best.	$74.0Best.	$90.4Best.
Revenue	$9.5B↑1%	$2.4B	$2.5B	$2.3B↑2%	$9.5B↑2%	$9.3B↑8%	$8.5B↑6%	$8.1B↑4%	$7.8B
Operating Income	--	--	--	--	--	--	--	--	--
Net Income	$2.5B↓6%	$591.0M↓18%	$691.0M↓4%	$601.0M↓5%	$2.7B↑8%	$2.5B↑6%	$2.3B↑11%	$2.1B↑4%	$2.0B
EPS (Diluted)	--	$1.44↓12%	$1.65↑2%	$1.42↑1%	$6.02↑10%	$5.47↑8%	$5.07↑13%	$4.49↑5%	$4.27
Gross Margin	—	—	—	—	71.8%↑2%	70.6%↑1%	70.0%↑1%	69.6%↓1%	70.4%
Operating Margin	—	—	—	—	—	—	—	—	—
ROE	75.3%↑53%	—	—	—	80.2%↑54%	52.1%↑11%	46.9%↓2%	48.0%↑7%	44.8%
Total Debt	$9.0B↑28%	$9.0B↑28%	$9.0B↑37%	$9.0B↑38%	$9.0B↑38%	$6.6B	$6.6B↓17%	$7.9B↑20%	$6.6B
Shareholders' Equity	$3.3B↓39%	$3.3B↓39%	$3.1B↓37%	$3.2B↓31%	$3.3B↓30%	$4.8B↓5%	$5.0B↑13%	$4.4B↓3%	$4.5B
Current Ratio	2.35↓36%	2.35↓36%	3.08↑75%	3.15↑82%	3.03↑73%	1.75↓48%	3.36↑42%	2.37↓39%	3.86
Debt / Equity	2.74↑109%	2.74↑109%	2.87↑117%	2.80↑98%	2.71↑97%	1.38↑5%	1.31↓27%	1.79↑24%	1.45
Operating Cash Flow	$2.8B↓5%	$824.0M↓12%	$655.0M↑35%	$401.0M↓32%	$2.9B↓2%	$3.0B↑25%	$2.4B↑23%	$1.9B↓14%	$2.2B
Free Cash Flow	$2.3B↑2%	$717.0M↓11%	$538.0M↑75%	$291.0M↓34%	$2.3B↓1%	$2.3B↑42%	$1.6B↑22%	$1.3B↓24%	$1.7B

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

ZTS vs Peers — Financial Grading

Revenue$9.5BMedian

Net Income$2.7BMedian

ROE80.2%Top 25%

D/E2.71Bottom 25%

Op. Margin—

Curr. Ratio3.03Median

Company	Market Cap	Price	Revenue	Net Income	ROE	D/E	Op. Margin	Curr. Ratio	Graham	Buffett	Lynch	Greenblatt	Piotroski	Dreman
Merck & Co., Inc.MRK	$364.3B	$147.76	$65.0B	$18.3B	34.7%	0.94	—	1.54	2/9	5/9	4/7	0/3	F-Score 4	1/11
ABBOTT LABORATORIESABT	$188.0B	$108.52	$44.3B	$6.5B	12.5%	0.25	18.2%	1.58	3/9	4/9	2/7	1/3	F-Score 5	3/11
BRISTOL MYERS SQUIBB COBMY	$129.7B	$63.43	$48.2B	$7.1B	38.2%	2.44	19.4%	1.26	2/9	1/9	3/7	1/3	F-Score 8	5/11
BIO-TECHNE CorpTECH	$11.4B	$72.80	$1.2B	$73.4M	3.8%	—	8.4%	3.46	4/9	3/9	3/7	0/3	F-Score 5	4/11
REPLIGEN CORPRGEN	$10.7B	$167.79	$738.3M	$48.9M	2.3%	0.26	7.5%	8.37	3/9	2/9	3/7	0/3	F-Score 7	5/11
IONIS PHARMACEUTICALS INCIONS	$4.8B	$29.06	$943.7M	$381.4M	-78.0%	3.60	-40.4%	3.83	3/9	1/9	1/7	0/3	F-Score 4	3/11
NEOGEN CORPNEOG	$2.5B	$11.23	$870.4M	$7.9M	-0.4%	0.76	-2.5%	3.82	3/9	1/9	2/7	0/3	F-Score 6	4/11
Pharvaris N.V.PHVS	$2.4B	$33.36	—	$206.4M	-64.8%	0.00	—	—	0/9	0/9	2/7	0/3	F-Score 2	2/11